Bildkälla: Stockfoto

Immunicum: SEK 141m Directed Issue - Redeye

Redeye regards the capital raise as an expected and logical step for Immunicum. A reduced financial risk should help shift focus to important near-term clinical catalysts.

Redeye regards the capital raise as an expected and logical step for Immunicum. A reduced financial risk should help shift focus to important near-term clinical catalysts.
Börsvärldens nyhetsbrev
ANNONSER